NRC Approval Advances Dow's Texas Nuclear Project but FID Remains Pending; Near-Term Financial Risk Unchanged

What happened

Dow has received NRC approval for its advanced nuclear project in Texas, a regulatory milestone that enables pursuit of zero-carbon power and steam for its operations. The approval does not commit Dow to construction; a final investment decision is still required and no cost or timeline has been disclosed. Dow's current financial position is strained: 2025 net loss of $2.62B, negative free cash flow of $(1.4B), net debt/EBITDA near 14x, and an ongoing $2B Transform to Outperform cost-restructuring program. While nuclear power could eventually lower energy costs and reduce emissions, its capital intensity conflicts with near-term cash preservation, especially after Dow already delayed Path2Zero and cut capex. The milestone is strategically positive but unlikely to affect near-term earnings or the wait-and-see investment case.

Implication

Investors should view the NRC approval as a regulatory checkbox rather than a catalyst; Dow has not committed capital and may delay the project further given its stretched balance sheet. The company's immediate priorities are delivering Transform to Outperform savings, restoring positive free cash flow, and deleveraging; a multi-billion-dollar nuclear build would compete with those goals. If Dow proceeds, it would add execution risk and potential equity dilution or dividend pressure without revenue benefit until the 2030s. Conversely, the option to pursue low-carbon power supports Dow's long-term cost position and sustainability credentials, but that is already partially reflected in the stock's premium valuation. Maintain the WAIT rating; a more constructive stance would require evidence of EBITDA uplift and leverage reduction before committing new capital.

Thesis delta

The NRC approval does not change our thesis; it adds a long-term strategic option but introduces potential future capital commitments that could further strain the balance sheet. We maintain the WAIT rating and the view that Dow's equity remains a higher-risk recovery trade dependent on self-help execution rather than a mispriced value opportunity. The approval might slightly improve the bull case's long-term cost advantage, but it does not affect near-term cash flow or leverage metrics.